Literature DB >> 30504296

Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist.

Tanya M Wildes1, Kenneth C Anderson2.   

Abstract

Mrs. A. is a 73-year-old woman who has developed increasing fatigue and lower back pain over the past year. The pain limits her exercise tolerance such that she can now walk only 1 block. She is a retired schoolteacher who does volunteer efforts in her community but has limited her activities due to fatigue. Karnofsky performance status is 70%. She has a history of chronic hypertension treated with a diuretic, adult-onset diabetes mellitus treated with metformin, and hypothyroidism treated with levothyroxine. Initial evaluation reveals anemia, renal dysfunction, an elevated total protein, and an L2 compression fracture on lumbosacral radiographs. Results of initial and subsequent evaluation are shown below, and she is referred to a hematologist for further evaluation, which revealed the following: calcium 9.0 mg/dL, creatinine 3.2 mg/dL with estimated creatinine clearance using the Modification of Diet in Renal Disease equation of 15 mL/min, hemoglobin 9.6 g/dL, total protein 11 g/dL, albumin 3.2 g/dL, immunoglobulin A (IgA) λ M protein 6.8 g/dL, total IgA 7.2 g/dL, IgG 0.4g/dL, IgM 0.03 g/dL, free κ <0.01 mg/L, free λ 1000 mg/L, serum free light chain ratio <0.01, β-2-microglobulin 4.2, viscosity 3.0, lactate dehydrogenase 200 U/L, urine protein electrophoresis: 125 mg/dL with 30% M protein, and urine immunofixation: λ light chain. Skeletal bone survey showed lytic lesions in femurs and humeri and diffusely in ribs bilaterally as well as compression fractures at T4, T6, and L2. Bone marrow biopsy revealed λ-restricted plasma cells comprising 50% of the bone marrow core. Fluorescence in situ hybridization testing on marrow showed that del 17p was present in 80% of the plasma cells. Mrs. A. is informed of the diagnosis of multiple myeloma and the need for therapy. She requests consultation with 2 of the leading world experts. However, she wants to be treated near her home and does not want treatment on a clinical trial.
© 2018 by The American Society of Hematology. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30504296      PMCID: PMC6245982          DOI: 10.1182/asheducation-2018.1.88

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  83 in total

1.  When the caregiver needs care: the plight of vulnerable caregivers.

Authors:  Maryam Navaie-Waliser; Penny H Feldman; David A Gould; Carol Levine; Alexis N Kuerbis; Karen Donelan
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

Review 2.  Untangling the concepts of disability, frailty, and comorbidity: implications for improved targeting and care.

Authors:  Linda P Fried; Luigi Ferrucci; Jonathan Darer; Jeff D Williamson; Gerard Anderson
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2004-03       Impact factor: 6.053

3.  Neuropathy in multiple myeloma treated with thalidomide: a prospective study.

Authors:  R Plasmati; F Pastorelli; M Cavo; E Petracci; E Zamagni; P Tosi; D Cangini; P Tacchetti; F Salvi; I Bartolomei; R Michelucci; C A Tassinari
Journal:  Neurology       Date:  2007-08-07       Impact factor: 9.910

Review 4.  Frailty in relation to the accumulation of deficits.

Authors:  Kenneth Rockwood; Arnold Mitnitski
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2007-07       Impact factor: 6.053

5.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

6.  Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study.

Authors:  Lazzaro Repetto; Lucia Fratino; Riccardo A Audisio; Antonella Venturino; Walter Gianni; Marina Vercelli; Stefano Parodi; Denise Dal Lago; Flora Gioia; Silvio Monfardini; Matti S Aapro; Diego Serraino; Vittorina Zagonel
Journal:  J Clin Oncol       Date:  2002-01-15       Impact factor: 44.544

7.  Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.

Authors:  Thomas J Pugh; Changhu Chen; Rachel Rabinovitch; S Gail Eckhardt; Kyle E Rusthoven; Robyn Swing; David Raben
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-02-03       Impact factor: 7.038

8.  Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Joan Bladé; Mario Boccadoro; Jamie D Cavenagh; Anthony L Boral; Dixie-Lee Esseltine; Patrick Y Wen; Anthony A Amato; Kenneth C Anderson; Jesus San Miguel
Journal:  Br J Haematol       Date:  2009-01-16       Impact factor: 6.998

9.  Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma.

Authors:  J M Hernández; R García-Sanz; E Golvano; J Bladé; J Fernandez-Calvo; J Trujillo; J A Soler; S Gardella; F Carbonell; G Mateo; J F San Miguel
Journal:  Br J Haematol       Date:  2004-10       Impact factor: 6.998

10.  Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.

Authors:  S Vincent Rajkumar; Susanna Jacobus; Natalie S Callander; Rafael Fonseca; David H Vesole; Michael E Williams; Rafat Abonour; David S Siegel; Michael Katz; Philip R Greipp
Journal:  Lancet Oncol       Date:  2009-10-21       Impact factor: 41.316

View more
  9 in total

1.  Geriatric assessment and quality of life changes in older adults with newly diagnosed multiple myeloma undergoing treatment.

Authors:  Hira Mian; Gregory R Pond; Sascha A Tuchman; Mark A Fiala; Tanya M Wildes
Journal:  J Geriatr Oncol       Date:  2020-05-27       Impact factor: 3.599

Review 2.  Re-defining Prognosis of Hematological Malignancies by Dynamic Response Assessment Methods: Lessons Learnt in Chronic Myeloid Leukemia, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma and Multiple Myeloma.

Authors:  Arihant Jain; Ankur Jain; Pankaj Malhotra
Journal:  Indian J Hematol Blood Transfus       Date:  2019-10-22       Impact factor: 0.900

Review 3.  Management of Newly Diagnosed Elderly Multiple Myeloma Patients.

Authors:  Crystal Antoine-Pepeljugoski; Marc Justin Braunstein
Journal:  Curr Oncol Rep       Date:  2019-05-24       Impact factor: 5.075

4.  How I treat a refractory myeloma patient who is not eligible for a clinical trial.

Authors:  Siyang Leng; Divaya Bhutani; Suzanne Lentzsch
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

5.  Treatment of older adult or frail patients with multiple myeloma.

Authors:  Shakira J Grant; Ciara L Freeman; Ashley E Rosko
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

6.  Opportunities for Participation in Randomized Controlled Trials for Patients with Multiple Myeloma: Trial Access Depends on Restrictive Eligibility Criteria and Patient Expectations.

Authors:  Amelie Boquoi; Veronika Rings; Annemarie Mohring; Ingrida Savickaite; Romans Zukovs; Judith Strapatsas; Kathrin Nachtkamp; Guido Kobbe; Ulrich Germing; Roland Fenk
Journal:  Cancers (Basel)       Date:  2022-04-26       Impact factor: 6.575

Review 7.  Transplant-ineligible newly diagnosed multiple myeloma: Current and future approaches to clinical care: A Young International Society of Geriatric Oncology Review Paper.

Authors:  Shakira J Grant; Hira S Mian; Smith Giri; Melina Boutin; Lorenzo Dottorini; Nina R Neuendorff; Jessica L Krok-Schoen; Nikita Nikita; Ashley E Rosko; Tanya M Wildes; Sonja Zweegman
Journal:  J Geriatr Oncol       Date:  2020-12-17       Impact factor: 3.599

Review 8.  Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of life.

Authors:  Evangelos Terpos; Joseph Mikhael; Roman Hajek; Ajai Chari; Sonja Zweegman; Hans C Lee; María-Victoria Mateos; Alessandra Larocca; Karthik Ramasamy; Martin Kaiser; Gordon Cook; Katja C Weisel; Caitlin L Costello; Jennifer Elliott; Antonio Palumbo; Saad Z Usmani
Journal:  Blood Cancer J       Date:  2021-02-18       Impact factor: 11.037

9.  Front-line treatment of multiple myeloma.

Authors:  Michele Cavo; Paola Tacchetti; Elena Zamagni
Journal:  Hemasphere       Date:  2019-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.